rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2021-11-01rpcardio-2622Research ArticleNOTES FROM PRACTICEКЛИНИЧЕСКИЙ ОПЫТPlasma Level’s of Neuregulin-1 in Healthy PeopleУровень циркулирующего нейрегулина-1 у здоровых добровольцевhttps://orcid.org/0000-0002-1574-3881ЖбановК. А.ZhbanovK. A.

Жбанов Константин Александрович.

Москва.

Konstantin A. Zhbanov.

Moscow.

https://orcid.org/0000-0002-8220-0350ЩендрыгинаА. А.ShchendryginaA. A.

Щендрыгина Анастасия Александровна.

Москва.

Anastasia A. Shchendrygina.

Moscow.

a.shchendrygina@gmail.comhttps://orcid.org/0000-0002-2596-192XЖелезныхЕ. А.ZheleznykhE. A.

Железных Елена Анатольевна.

Москва.

Elena A. Zheleznykh.

Moscow.

https://orcid.org/0000-0002-9908-9476ПриваловаЕ. В.PrivalovaE. V.

Привалова Елена Витальевна.

Москва.

Elena V. Privalova.

Moscow.

https://orcid.org/0000-0002-2224-0019СуворовА. Ю.SuvorovA. Y.

Суворов Александр Юрьевич.

Москва.

Alexander Y. Suvorov.

Moscow.

https://orcid.org/0000-0002-6750-5201АбляметоваА. С.AblyametovaA. S.

Абляметова Авашерфе Сапуетовна.

Москва.

Avasherfe S. Ablyametova.

Moscow.

https://orcid.org/0000-0002-3869-4576ФуксманН. Ф.FuksmanN. F.

Фуксман Нелли Феликсовна.

Москва.

Nelli F. Fuksman.

Moscow.

https://orcid.org/0000-0003-4323-9671СалахееваЕ. Ю.SalakheevaE. Yu.

Салахеева Екатерина Юрьевна.

Москва.

Ekaterina Yu. Salakheeva.

Moscow.

https://orcid.org/0000-0002-3014-6129БеленковЮ. Н.BelenkovYu. N.

Беленков Юрий Никитич.

Москва.

Yuri N. Belenkov.

Moscow.

Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University)Russian Federation202112012022176853859Copyright © Zhbanov K.A., Shchendrygina A.A., Zheleznykh E.A., Privalova E.V., Suvorov A.Y., Ablyametova A.S., Fuksman N.F., Salakheeva E.Y., Belenkov Y.N., 20222022Жбанов К.А., Щендрыгина А.А., Железных Е.А., Привалова Е.В., Суворов А.Ю., Абляметова А.С., Фуксман Н.Ф., Салахеева Е.Ю., Беленков Ю.Н.Zhbanov K.A., Shchendrygina A.A., Zheleznykh E.A., Privalova E.V., Suvorov A.Y., Ablyametova A.S., Fuksman N.F., Salakheeva E.Y., Belenkov Y.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/2622Aim

Aim. To determine the median levels of neuregulin-1 (NRG-1; endothelium-derived growth factor and the natural agonist of the ERBB3 and ERBB4 receptors) NRG-1 in healthy volunteers and to study the associations of NRG-1 levels with gender and age.

Material and Methods

Material and Methods. Ninety seven healthy participants were enrolled (median age of 44 [32-54], men 45 men [46.4%]). The following age groups were identified: 20-29 y.о. (n=20, men – 50.0%),  30-39  y.о.  (n=21,  men  –  52.4%),  40-49  y.о.  (n=22,  men  –  45.5%),  50-59  y.о. (n=22, men – 36.4%); 60-69 y.о. (n=12, men – 50.0%). Peripheral blood samples were collected at the time of enrolment, standard laboratory tests were performed, and NRG-1 levels were determined in the plasma samples by ELISA.

Results

Results. In the cohort of 97 healthy participants the median value of NRG-1 was 0.3 [0.121-2.24] ng/ml. NRG-1 levels did not differ significantly between men and women (p=0.145), indicating that NRG-1 levels are not influenced by gender. The levels of NRG-1 were similar in the different age groups: age 20-29 years=0.26 [0.17-0.37] ng/ml; age 30-39=0.24 [0.1-0.39] ng/ml; age 40-49=0.31 [0.19-1.15] ng/ml; age 50-59=0.37  [0.19-1.0] ng/ml; age 60-69=0.4 [0.13-0.81] ng/ml. Correlation analysis between NRG-1 levels and route blood measurements (haemoglobin, lipids, glucose, creatinine, and uretic acid) did not show significant associations.

Conclusions

Conclusions. In this study, the median value of NRG-1 plasma levels were determined. The results of the study show that age and gender had no influence on NRG-1 values.

Цель

Цель. Определить концентрацию циркулирующего нейрегулина-1 (NRG-1; эндотелиальный фактор роста, естественный агонист ERBB3/ERBB4-рецепторов тирозинкиназы) в плазме крови здоровых добровольцев, а также изучить ассоциации уровня NRG-1 с полом и возрастом.

Материал и методы

Материал и методы. В исследование было включено 97 здоровых добровольцев (45 [46,4%] мужчин; медиана возраста 45 [32-54] лет). Выделены следующие возрастные группы: 20-29 лет (n=20; 50,0% мужчин), 30-39 лет (n=21; 52,4% мужчины), 40-49 лет (n=22; 45,5% мужчин), 50-59 лет (n=22; 36,4% мужчин); 60-69 лет (n=12; 50,0% мужчин). Всем пациентам выполнен общий и биохимический анализ крови. Определение уровня NRG-1 проводилось методом иммуноферментного анализа.

Результаты

Результаты. Медианное значение NRG-1 составило 0,3 [0,121-2,24] нг/мл. Уровни NRG-1 были схожими в разных возрастных группах: 20-29 лет=0,26 [0,17-0,37] нг/мл; 30-39=0,24 [0,1-0,39] нг/мл; 40-49=0,31 [0,19-1,15] нг/мл; возраст 50-59=0,37 [0,19-1,0] нг/мл; 60-69=0,4 [0,13-0,81] нг/мл. Статистически значимых различий между концентрациями NRG-1 у мужчин и женщин выявлено не было (p=0,145). Связи уровня NRG-1 с лабораторными показателями (гемоглобин, липидный спектр, глюкоза, креатинин и мочевая кислота) не отмечено.

Заключение

Заключение. В ходе исследований определены средние значения NRG-1 плазмы крови у здоровых лиц. Влияние пола и возраста на концентрацию биомаркера не выявлено. Полученные данные помогут в интерпретации изменений уровня NRG-1 у лиц с различной патологией в дальнейших исследованиях.

нейрегулин-1NRG-1ERBB3ERBB4Neuregulin-1NRG-1ERBB3ERBB4Исследование выполнено при финансовой поддержке РФФИ в рамках научного проекта №18-515-76002, научного гранта «Роль Нейрегулина-1 в развитии и прогрессировании сердечно-сосудистой патологии: выявление агониста ErbB4 рецептора и приоритетных групп терапии».ReferencesRyzhov S, Matafonov A, Galindo CL, et al. ERBB signaling attenuates proinflammatory activation of nonclassical monocytes. Am J Physiol Heart Circ Physiol. 2017;312(5):H907-H918. DOI:10.1152/ajp-heart.00486.2016.Ryzhov S, Matafonov A, Galindo CL, et al. ERBB signaling attenuates proinflammatory activation of nonclassical monocytes. Am J Physiol Heart Circ Physiol. 2017;312(5):H907-H918. DOI:10.1152/ajp-heart.00486.2016.Liu W, Zscheppang K, Murray S, et al. The ErbB4 receptor in fetal rat lung fibroblasts and epithelial type II cells. Biochim Biophys Acta. 2007;1772(7):737-47. DOI:10.1016/j.bbadis.2007.04.008.Liu W, Zscheppang K, Murray S, et al. The ErbB4 receptor in fetal rat lung fibroblasts and epithelial type II cells. Biochim Biophys Acta. 2007;1772(7):737-47. DOI:10.1016/j.bbadis.2007.04.008.Xu Z, Ford GD, Croslan DJR, et al. Neuroprotection by neuregulin-1 following focal stroke is associated with the attenuation of ischemia-induced pro-inflammatory and stress gene expression. Neurobiol Dis. 2005;19(3):461-70. DOI:10.1016/j.nbd.2005.01.027.Xu Z, Ford GD, Croslan DJR, et al. Neuroprotection by neuregulin-1 following focal stroke is associated with the attenuation of ischemia-induced pro-inflammatory and stress gene expression. Neurobiol Dis. 2005;19(3):461-70. DOI:10.1016/j.nbd.2005.01.027.Mograbi B, Rochet N, Imbert V, et al. Human monocytes express amphiregulin and heregulin growth factors upon activation. Eur Cytokine Netw. 1997;8(1):73-81.Mograbi B, Rochet N, Imbert V, et al. Human monocytes express amphiregulin and heregulin growth factors upon activation. Eur Cytokine Netw. 1997;8(1):73-81.De Keulenaer GW, Feyen E, Dugaucquier L, et al. Mechanisms of the Multitasking Endothelial Protein NRG-1 as a Compensatory Factor during Chronic Heart Failure. Circ Heart Fail. 2019;12(10):1-15. DOI:10.1161/CIRCHEARTFAILURE.119.006288.De Keulenaer GW, Feyen E, Dugaucquier L, et al. Mechanisms of the Multitasking Endothelial Protein NRG-1 as a Compensatory Factor during Chronic Heart Failure. Circ Heart Fail. 2019;12(10):1-15. DOI:10.1161/CIRCHEARTFAILURE.119.006288.Galindo CL, Ryzhov S, Sawyer DB. Neuregulin as a heart failure therapy and mediator of reverse remodeling. Curr Heart Fail Rep. 2014;11(1):40-9. DOI: 10.1007/s11897-013-0176-2.Galindo CL, Ryzhov S, Sawyer DB. Neuregulin as a heart failure therapy and mediator of reverse remodeling. Curr Heart Fail Rep. 2014;11(1):40-9. DOI: 10.1007/s11897-013-0176-2.García-Rivello H, Taranda J, Said M, et al. Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle. Am J Physiol Heart Circ Physiol. 2005;289(3):H1153-60. DOI:10.1152/ajpheart.00048.2005.García-Rivello H, Taranda J, Said M, et al. Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle. Am J Physiol Heart Circ Physiol. 2005;289(3):H1153-60. DOI:10.1152/ajpheart.00048.2005.Russell KS, Stern DF, Polverini PJ, Bender JR. Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am J Physiol Heart Circ Physiol. 1999;277(6):H2205-11. DOI:10.1152/ajpheart.1999.277.6.h2205.Russell KS, Stern DF, Polverini PJ, Bender JR. Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am J Physiol Heart Circ Physiol. 1999;277(6):H2205-11. DOI:10.1152/ajpheart.1999.277.6.h2205.Lemmens K, Segers VFM, Demolder M, De Keulenaer GW. Role of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk. J Biol Chem. 2006;281(28):19469-77. DOI:10.1074/jbc.M600399200.Lemmens K, Segers VFM, Demolder M, De Keulenaer GW. Role of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk. J Biol Chem. 2006;281(28):19469-77. DOI:10.1074/jbc.M600399200.Galindo CL, Kasasbeh E, Murphy A, et al. Anti‐Remodeling and Anti‐Fibrotic Effects of the Neuregulin‐1b Glial Growth Factor 2 in a Large Animal Model of Heart Failure. J Am Heart Assoc. 2014;3(5):000773. DOI:10.1161/jaha.113.000773.Galindo CL, Kasasbeh E, Murphy A, et al. Anti‐Remodeling and Anti‐Fibrotic Effects of the Neuregulin‐1b Glial Growth Factor 2 in a Large Animal Model of Heart Failure. J Am Heart Assoc. 2014;3(5):000773. DOI:10.1161/jaha.113.000773.Bersell K, Arab S, Haring B, Kühn B. Neuregulin1/ErbB4 Signaling Induces Cardiomyocyte Proliferation and Repair of Heart Injury. Cell. 2009;138(2):257-70. DOI:10.1016/j.cell.2009.04.060.Bersell K, Arab S, Haring B, Kühn B. Neuregulin1/ErbB4 Signaling Induces Cardiomyocyte Proliferation and Repair of Heart Injury. Cell. 2009;138(2):257-70. DOI:10.1016/j.cell.2009.04.060.Gao R, Zhang J, Cheng L, et al. A phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol. 2010;55(18):1907-14. DOI:10.1016/j.jacc.2009.12.Gao R, Zhang J, Cheng L, et al. A phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol. 2010;55(18):1907-14. DOI:10.1016/j.jacc.2009.12.Jabbour A, Hayward CS, Keogh AM, et al. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail. 2011;13(1):83–92. DOI:10.1016/j.jacc.2009.12.044.Jabbour A, Hayward CS, Keogh AM, et al. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail. 2011;13(1):83–92. DOI:10.1016/j.jacc.2009.12.044.Geisberg CA, Wang G, Safa RN, et al. Circulating neuregulin-1b levels vary according to the angiographic severity of coronary artery disease and ischemia. Coron Artery Dis. 2011;22(8):577-82. DOI:10.1097/MCA.0b013e32834d3346.Geisberg CA, Wang G, Safa RN, et al. Circulating neuregulin-1b levels vary according to the angiographic severity of coronary artery disease and ischemia. Coron Artery Dis. 2011;22(8):577-82. DOI:10.1097/MCA.0b013e32834d3346.Geisberg CA, Abdallah WM, Da Silva M, et al. Circulating neuregulin during the transition from stage a to stage B/C heart failure in a breast cancer cohort. J Card Fail. 2013;19(1):10-5. DOI:10.1016/j.cardfail.2012.11.006.Geisberg CA, Abdallah WM, Da Silva M, et al. Circulating neuregulin during the transition from stage a to stage B/C heart failure in a breast cancer cohort. J Card Fail. 2013;19(1):10-5. DOI:10.1016/j.cardfail.2012.11.006.Ky B, Kimmel SE, Safa RN, et al. Neuregulin-1b is associated with disease severity and adverse outcomes in chronic heart failure. Circulation. 2009;120(4):310-7. DOI:10.1161/CIRCULATIONAHA.109.856310.Ky B, Kimmel SE, Safa RN, et al. Neuregulin-1b is associated with disease severity and adverse outcomes in chronic heart failure. Circulation. 2009;120(4):310-7. DOI:10.1161/CIRCULATIONAHA.109.856310.Zeng Z, Gui C, Nong Q, et al. Serum neuregulin-1b levels are positively correlated with VEGF and Angiopoietin-1 levels in patients with diabetes and unstable angina pectoris. Int J Cardiol. 2013;168(3):3077-9. DOI:10.1016/j.ijcard.2013.04.088.Zeng Z, Gui C, Nong Q, et al. Serum neuregulin-1b levels are positively correlated with VEGF and Angiopoietin-1 levels in patients with diabetes and unstable angina pectoris. Int J Cardiol. 2013;168(3):3077-9. DOI:10.1016/j.ijcard.2013.04.088.Hage C, Wärdell E, Linde C, et al. Circulating neuregulin1-b in heart failure with preserved and reduced left ventricular ejection fraction. ESC Hear Fail. 2020;7(2):445-55. DOI:10.1002/ehf2.12615.Hage C, Wärdell E, Linde C, et al. Circulating neuregulin1-b in heart failure with preserved and reduced left ventricular ejection fraction. ESC Hear Fail. 2020;7(2):445-55. DOI:10.1002/ehf2.12615.Naresh A, Long W, Vidal GA, et al. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res. 2006;66(12):6412-20. DOI:10.1158/0008-5472.CAN-05-2368.Naresh A, Long W, Vidal GA, et al. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res. 2006;66(12):6412-20. DOI:10.1158/0008-5472.CAN-05-2368.Miao J, Huang S, Su YR, Lenneman CA, et al. Effects of endogenous serum neuregulin-1b on morbidity and mortality in patients with heart failure and left ventricular systolic dysfunction. Biomarkers. 2018;23(7):704-8. DOI:10.1080/1354750X.2018.1485054.Miao J, Huang S, Su YR, Lenneman CA, et al. Effects of endogenous serum neuregulin-1b on morbidity and mortality in patients with heart failure and left ventricular systolic dysfunction. Biomarkers. 2018;23(7):704-8. DOI:10.1080/1354750X.2018.1485054.Wang R, Wang Y, Hu R, et al. Decreased plasma levels of neureglin-1 in drug naïve patients and chronic patients with schizophrenia. Neurosci Lett. 2015;606:220-4. DOI:10.1016/j.neulet.2015.09.010.Wang R, Wang Y, Hu R, et al. Decreased plasma levels of neureglin-1 in drug naïve patients and chronic patients with schizophrenia. Neurosci Lett. 2015;606:220-4. DOI:10.1016/j.neulet.2015.09.010.Shibuya M, Komi E, Wang R, et al. Measurement and comparison of serum neuregulin 1 immunoreactivity in control subjects and patients with schizophrenia: An influence of its genetic polymorphism. J Neural Transm. 2010;117(7):887-95. DOI:10.1007/s00702-010-0418-3.Shibuya M, Komi E, Wang R, et al. Measurement and comparison of serum neuregulin 1 immunoreactivity in control subjects and patients with schizophrenia: An influence of its genetic polymorphism. J Neural Transm. 2010;117(7):887-95. DOI:10.1007/s00702-010-0418-3.

The authors declare that there are no conflicts of interest present.